We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





World's First 5-Minute Real-Time PCR Instrument Debuts at ADLM 2024

By LabMedica International staff writers
Posted on 30 Jul 2024
Print article
Image: The XDive 5-minute real-time PCR instrument is on display at ADLM 2024 (Photo courtesy of OnsiteGene Inc.)
Image: The XDive 5-minute real-time PCR instrument is on display at ADLM 2024 (Photo courtesy of OnsiteGene Inc.)

OnsiteGene Inc. (San Diego, CA, USA) is introducing the new XDive, the world's first 5-minute real-time PCR instrument, at the Association for Diagnostics & Laboratory Medicine (ADLM) 2024 conference. This groundbreaking innovation completes 40 thermal cycles and real-time fluorescent imaging in just five minutes while maintaining sensitivity comparable to leading brands on the market.

OnsiteGene's XDive 5-minute PCR is an ultra-fast real-time PCR analysis platform that integrates high-speed thermal cycling, ultra-fast PCR reaction reagents, and real-time fluorescence data acquisition workflows. XDive can perform up to 16 ultra-fast reactions per experiment, providing moderate sample throughput and maximum working flexibility. It uses proprietary heating blocks, sensors, and algorithms to achieve ultra-fast ramp rates and superior temperature control accuracy. Its optical system consists of four fluorescence channels, which can be detected by multiplex real-time PCR analysis in minutes. XDive's unique TaqMan chemistry has been optimized for ultra-fast operating conditions. XDive reaction tubes accommodate reaction volumes on conventional PCR instruments, resulting in highly accurate and reproducible results for very ultra-fast fluorescence PCR analysis. The software structure of the system is simple and reasonable, and it is easy to operate.

OnsiteGene's original XDive 5-minute ultra-fast real-time PCR instrument can be easily integrated into new systems as an OEM module, significantly increasing productivity and flexibility, as well as reducing application costs. With OnsiteGene’s 5 minutes superfast magnetic bead nucleic acid extraction instrument (Xtractor) and reagent, users can also develop new ultra-fast real-time PCR applications on the XDive system with 16 sample throughput in as fast as 10 minutes from sample to answer for point-of-care molecular testing and other applications. The instrument has received FDA Emergency Use Authorization (EUA) for COVID-19 and Monkeypox testing using swab or saliva samples.

XDive's editable panel technology simplifies the regulatory process for developing test kits and syndromic panels, significantly reducing time, cost, and risk. The superfast master mix used in the XDive instrument is in a dried form, allowing for easy shipping and storage at room temperature with a shelf life of 6 months. OnsiteGene has also developed the XPrep module, designed to extract RNA/DNA and seamlessly load XDive cartridges. With the XPrep module, XDive instruments provide a comprehensive and flexible sample-to-answer platform with up to 96-sample throughput, up to 256 multiplexing targets, and a 30-minute turnaround time.

Related Links:
OnsiteGene Inc.

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.